1. Volume 89, Issue 3, Pages 701-711 (March 2016)
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome 
Larry A. Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I. Al-Akash, Jonathan Evans, Paul Henning, Kenneth V. Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole C.A.J. van de Kar, Johan Vande Walle, Masayo Ogawa, Camille L. Bedrosian, Christoph Licht 
Kidney International 
Volume 89, Issue 3, Pages (March 2016)
DOI: /j.kint
Copyright © 2016 International Society of Nephrology Terms and Conditions

2. Figure 1
Patient disposition. aLDH ≥ 1.5 × ULN; hemoglobin ≤ LLN; fragmented red blood cells with a negative Coombs test result. bOne patient had a positive test for STEC infection, 1 had a normalized platelet count; 2 had a final diagnosis that was not aHUS, 1 had unspecified reasons. aHUS, atypical hemolytic uremic syndrome; LDH, lactate dehydrogenase; LLN, lower limit of normal; SAE, serious adverse event; SCr, serum creatinine; STEC, Shiga-like toxin-producing Escherichia coli; ULN, upper limit of normal.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

3. Figure 2
Improvement in platelet count over 27 weeks of eculizumab treatment. N values <5 were not included. Bars represent SEM. Arrows denote administration of eculizumab.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

4. Figure 3
Improvement in platelet count over 27 weeks of eculizumab treatment in individual patients.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

5. Figure 4
Improvement in estimated glomerular filtration rate (eGFR) over 27 weeks of eculizumab treatment. N values <5 were not included. Bars represent SEM. Arrows denote administration of eculizumab.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

6. Figure 5
Improvement in estimated glomerular filtration rate (eGFR) over 27 weeks of eculizumab treatment in individual patients.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions